Upregulation of Cellular Bcl-2 by the KSHV Encoded RTA Promotes Virion Production by Gao, Jianming et al.
Upregulation of Cellular Bcl-2 by the KSHV Encoded RTA
Promotes Virion Production
Jianming Gao
1,2, Qiliang Cai
1,J i eL u
1, Hem Chandra Jha
1, Erle S. Robertson
1*
1Department of Microbiology and the Tumor Virology Program of the Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, Pennsylvania, United States of America, 2Department of Pathophysiology, Three Gorges University School of Medicine, Yichang, Hubei, China
Abstract
Apoptosis of virus infected cells can restrict or dampen full blown virus propagation and this can serve as a protective
mechanism against virus infection. Consequently, viruses can also delay programmed cell death by enhancing the
expression of anti-apoptotic proteins. Human Bcl-2 is expressed on the surface of the mitochondrial membrane and
functions as the regulator of the delicate balance between cell survival and apoptosis. In this report, we showed that the
replication and transcription activator (RTA) encoded by KSHV ORF 50, a key regulator for KSHV reactivation from latent to
lytic infection, upregulates the mRNA and protein levels of Bcl-2 in 293 cells, and TPA-induced KSHV-infected cells. Further
analysis revealed that upregulation of the cellular Bcl-2 promoter by RTA is dose-dependent and acts through targeting of
the CCN9GG motifs within the Bcl-2 promoter. The Bcl-2 P2 but not the P1 promoter is primarily responsive to RTA. The
results of ChIP confirmed the direct interaction of RTA protein with the CCN9GG motifs. Knockdown of cellular Bcl-2 by
lentivirus-delivered small hairpin RNA (shRNA) resulted in increased cell apoptosis and decreased virion production in KSHV-
infected cells. These findings provide an insight into another mechanism by which KSHV utilizes the intrinsic apoptosis
signaling pathways for prolonging the survival of lytically infected host cells to allow for maximum production of virus
progeny.
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Introduction
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV), the etiolog-
ical factor associated with Kaposi’s Sarcoma is also known as
human herpesvirus 8 (HHV 8). Several other malignancies such as
primary effusion lymphoma, and multicentric Castleman’s disease
have also been known to associate with KSHV [1,2,3,4]. KSHV
belongs to the c-herpesviruses family, the life cycle of which
consists of two distinct phases, latent and lytic replication [5,6,7,8].
During latency, the virus establishes persistent infection and only a
small subset of genes such as ORF73, K12, ORF72, ORF71 and
K15 are typically expressed [9,10]. Under conditions of lytic
reactivation such as hypoxia the virus spreads to new target cells
and the viral genes are activated in cascade mode [11,12,13]. The
switch to lytic reactivation is experimentally induced by a number
of intracellular or extracellular motivators including the chemical
agents 12-O-tetradecanoyl phorbol-13 acetate (TPA) and sodium
butyrate [14,15].
RTA, encoded by KSHV ORF 50, is an immediate early
protein and functions as the critical regulator for the shift of
KSHV life cycle from latency to lytic activation. Studies have
previously shown that RTA is able to activate the transcription of
many viral genes, including K1 [16], K2 [17], K3 [18], K5 [19],
K8 [20,21], K9 [22], K12 [23], K14[24], K15 [25], PAN RNAs
[23,26,27], ORF35 [28], ORF49 [29], ORF50 itself [30,31], K57
[32,33], and K59 [34]. Furthermore, increased RTA expression
which may be a result of expression from exogenous or
endogenous sources is sufficient to disrupt viral latency and
initiate KSHV lytic replication leading to the cascade reactivation
of viral genes, host cell death and release of viral progeny.
Apoptosis is a major antiviral cellular response against viral
infection. The B-cell leukemia/lymphoma 2 (Bcl-2) family of
proteins controls the intrinsic mitochondrial pathway of cellular
apoptosis [35,36]. The Bcl-2 group of proteins is classified as pro-
and anti- apoptotic members, all of which contain at least one
highly conserved Bcl-2 homology (BH) domain [37]. The anti-
apoptotic proteins, such as Bcl-2, Mcl-1, and Bcl-xL, share BH
domains 1–4 [38]. The pro-apoptotic members include the Bax
and the BH3-only families. The members of the bax family such as
bax, bak share BH domains 1–3, and the BH3-only families have
only the short BH3 motif respectively. This BH3 motif plays a
central role in the killing action of molecules [37]. Moreover, Bcl-2
functions as one of the important regulators to maintain the
delicate balance between cell survival and apoptosis. The human
Bcl-2 gene is overexpressed in numerous human cancers, including
B- and T- cell lymphomas, cervical, lung, breast, prostate and
colorectal cancers [39,40,41,42,43,44]. Its overexpression in tumor
cells not only functions as an apoptosis inhibitor, but also results in
resistance to chemotherapy or radiotherapy-induced apoptosis
[45,46]. Thus, because of its function in anti-apoptosis, the Bcl-2
gene has become a strong potential target in development of
anticancer therapies [47,48,49].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23892Bcl-2 protein levels can be regulated transcriptionally and post
transcriptionally. Furthermore, the human Bcl-2 gene contains
both the P1 and P2 promoters [47,49]. P1, the predominant
promoter, is located 1.3- to 1.5-kbp upstream of the translation
start site. The P1 promoter is mainly GC rich, with a number of
transcription initiation sites and includes seven consensus binding
sites for the Sp1 transcription factor. However, the P2 promoter
has canonical CAAT as well as TATA boxes [47,49]. Some
transcriptional factors such as CREBP (cAMP responsive element
binding protein), and NFkB are known to be positive regulators of
Bcl-2 transcription, and a few negative regulatory sites have also
been described, including WT1, p53 binding sites [47]. Studies
have shown that G-quadruplex structure upstream of the P1
promoter plays a role in transcription regulation [48,49]. In
addition, Bcl-2 may also be modified post-translationally by
phosphorylation which occurs at mitogen-activated protein kinase
(MAPK) sites which can trigger proteasome-dependent degrada-
tion and ubiquitination [50]. Caspase-dependent cleavage can also
occur leading to loss of its anti-apoptotic activity [50].
We now show that RTA can transactivate the cellular Bcl-2
promoter in a dose-dependent manner. RTA upregulates Bcl-2
through targeting of CCN9GG-like RTA responsive elements
(RREs) within the promoter and that the P2 promoter is important
for RTA-mediated transcriptional regulation of cellular Bcl-2.
These findings provide insights into new mechanisms by which
RTA transactivates cellular Bcl-2 and so contributes to enhanced
efficiency of KSHV lytic replication.
Results
Bcl-2 transcipts and protein levels are elevated in cells
transiently expressing RTA
Bcl-2 mRNA transcripts and protein levels were examined to
specifically detect the RTA-mediated cellular Bcl-2 upregulation
(Fig. 1). HEK 293 and DG75 cells were transiently transfected
with increasing amounts of RTA expression plasmid. Total RNAs
were isolated from cells for use in RT-PCR assay. The results of
the RT-PCR analysis showed that RTA clearly enhanced the Bcl-
2 transcript levels in a dose- dependent manner. Furthermore,
results of Western blot analyses also supported increased
upregulation of Bcl-2 protein in a dose-dependent manner
(Fig. 1A, B). Therefore, expression of RTA directly affects the
transcription of Bcl-2 and upregulates Bcl-2 protein levels.
Bcl-2 expression is upregulated in TPA-induced KSHV-
infected BC3 and BCBL1 cells
KSHV lytic replication can be initiated by chemical inducers,
like TPA and sodium butyrate [51]. Being an immediate early
protein, expression of RTA can be observed at the first hour after
TPA treatment [55,56,57]. To determine the changes in Bcl-2
level in KSHV induced cells, KSHV was induced from BC3 and
BCBL1 cells as mentioned above and cells were harvested for
analysis. The results from our RT-PCR and Western blot analyses
showed that Bcl-2 expression were strongly upregulated in TPA
and butyrate induced KSHV-positive B cells (Fig. 2A, B). In
contrast, there was no background RTA expression in uninduced
cells subjected to the same analysis, and as expected in the KSHV-
negative BJAB cell there was no RTA expression after induction.
Moreover, the expression of Bcl-2 mRNA and protein in BJAB
cells when treated with TPA had little or no obvious effect when
uninduced cells were compared to the induced cells suggesting that
the upregulation of Bcl-2 is due to the presence of KSHV and the
viral induced factor RTA (Fig. 2).
The levels of Bcl-2 mRNA is enhanced in RTA-expressing
HEK 293 cells and in KSHV-infected B cells induced for
lytic replication
In addition to RT-PCR analysis, we wanted to corroborate our
results and so performed Northern blot analysis to verify Bcl-2-
specific mRNA in RTA expressing HEK 293 cells and in induced
KSHV-infected B cells by using a Bcl-2-specific DNA probe.
Results showed that the levels of total Bcl-2 mRNA were strongly
increased in a dose-dependent manner in HEK 293 cells
transfected with the RTA expression plasmid. Additionally, total
Bcl-2 mRNA expression in TPA induced BC3 and BCBL1 cells
was also strongly enhanced compared to uninduced cells with no
evidence of change in KSHV negative BJAB cells. The same blots
were re-probed with a GAPDH specific probe as control. The
density of Bcl-2 signal was normalized against that of the GAPDH
control to quantify the levels of Bcl-2 mRNA expression and was
presented as a histogram for relative density levels (Fig. 3).
RTA activates the Bcl-2 gene promoter in a dose-
dependent manner
Since TPA-induced KSHV-infected cells and RTA expressing cells
showed higher levels of Bcl-2 mRNA and protein expression, we
further explored the molecular mechanism of Bcl-2 promoter up-
regulation by RTA. To analyze the role of RTA on regulating the Bcl-
2 promoter, a fixed amount of full length Bcl-2 promoter luciferase
construct (pGL3-Bcl-2) [47,49], was cotransfected with increasing
amounts of pcDNA-RTA into HEK 293 and DG75 cells. After 24 h,
the cells were harvested for luciferase reporter assay. The reporter
assays showed that RTA can indeed activate the Bcl-2 promoter by
approximately 12 to 35-fold compared to that of the vector alone in
HEK 293 cells as well as 5 to 25-fold in DG75 cells (Fig. 4 A and B).
These results suggest that RTA can up-regulate Bcl-2 expression
through regulation of cis-acting elements in the promoter.
The P2 promoter and the CCN9GG domains both
contribute to Bcl-2 promoter activation by RTA
To identify the potential motifs indispensable for the upregula-
tion of cellular Bcl-2 by RTA, a series of truncated promoter
luciferase contructs were generated and tested by reporter analysis
in both HEK 293 and DG75, as shown in Fig. 5 A to C.
The two promoters P1 and P2 [47,49] and 9 CCN9GG-like
RTA-responsive elements (RREs) are located within the full length
Bcl-2 promoter (Fig. 5A). The CCN9GG-like sequences within the
Bcl-2 promoter are similar to one of the RREs identified in the
KSHV ORF57 promoter [58]. To identify which of these motifs
play a critical role in regulating transcription of the Bcl-2 promoter
by RTA, three truncations of the promoter named pGL3-DRREs,
pGL3-DP1, pGL3-DP2 were generated to delete the RREs, the P1
and the P2 promoters, respectively. These promoter constructs
were transfected into HEK 293 and DG75 cell lines with different
amounts of RTA plasmids. As shown in the Fig. 5B and C, the
deletion of P1 promoter did not result in change in promoter
activity in HEK 293 cells (Fig. 5B). In contrast, deletion of P2
promoter as well as the deletion of the 9 CCN9GG-like RREs
resulted in a complete shutdown of the promoter activity with an
almost negligible change in activity when compared to promoter
alone without RTA expression. Our data strongly indicated that
the P2 promoter region and the CCN9GG domains were
indispensable for RTA-mediated upregulation of Bcl-2.
To confirm the role of the CCN9GG motifs in Bcl-2 regulation,
we performed reporter assays by using the pGL3-DRRE1,2
luciferase construct in which the first and second CCN9GG motifs
were deleted (Fig. 6A). We found that mutation of the first and
RTA-Mediated Upregulation of Bcl-2
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diminished promoter activity compared with that of the pGL3-DP1
alone (Fig. 6B). First of all without RTA there was little or no activity
comparable to basic luciferase vector alone. However, with the RTA
expression construct the results showed about a 10 fold increase with
the DRRE1,2, but a decrease of approximately 3 times compared to
the DP1 reporter which contained all the RREs (Fig. 6B). This
suggests that the CCN9GG motifs within the Bcl-2 definitely play a
critical role in RTA-mediated regulation of this promoter. To show
direct interaction of RTA protein with the CCN9GG motifs, CHIP
was carried out using induced and uninduced BCBL1 cells. The
presence of the first and second CCN9GG motifs within the
immunoprecipitated complex was confirmed by PCR amplification.
A clear band was detected in RTA antibody precipitated induced
nuclei DNA, whereas there is no signal in RTA antibody
precipitated uninduced nuclei DNA, and the two IgG negative
controls failed to recover any PCR product (Fig. 6C, upper panel).
Real-time PCR wasalso usedtoquantify theprecipitated DNA. The
amount of RTA antibody precipitated induced nuclei DNA was
about 8 to 32 times higher when compared with that of the control
groups (Fig. 6C, bottom panel).
Bcl-2 expression is important for prolonged survival of
lytically infected host cells and contributes to enhanced
production of virus progeny
On the basis of the results we observed above, we hypothesized
that RTA could take advantage of the Bcl-2 pathway to promote
cell survival which may result in enhanced virus progeny
production. Hence, we wanted to determine whether upregulation
Figure 1. Bcl-2 is upregulated in HEK 293 and DG 75 cells tranfected with RTA. (A) Quantification of Bcl-2 transcripts by RT-PCR. Total RNA
was ectracted from 10 million HEK 293 and DG 75 cells tranfected with increasing amount of RTA plasmid (0, 5, 10, 15 mg). A total of 2 mg of RNA was
used to synthesize cDNA. Real-time PCR was performed by using a power SYBR green PCR Master Mix kit with GAPDH as control. Standard deviations
were illustrated by error bars. (B) Western blot (WB) analysis of endogenous Bcl-2 in the RTA-expressing HEK 293. GAPDH was used for internal
control. Quantification of the relative densities of Bcl-2 was plotted below the blots.
doi:10.1371/journal.pone.0023892.g001
Figure 2. Bcl-2 is upregulated in TPA and butyrate induced BC3, BCBL1 cells. (A) Quantification of Bcl-2 transcripts by RT-PCR. (B) Western
blot analysis of endogenous Bcl-2 in induced and uninduced BC3, BCBL1, BJAB cells.
doi:10.1371/journal.pone.0023892.g002
RTA-Mediated Upregulation of Bcl-2
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constructed stable Bcl-2 knockdown cells (BC3-shBcl2, BJAB-
shBcl2) and their control cells (BC3-shC,B JAB-shC) by lentivirus
infection and puromycin selection (Fig. 7A). The expression of Bcl-2
in the Bcl-2knockdown and the controlcell lines were monitored by
Westernblot. Bcl-2protein level was considerably decreased in both
BJAB and BC3 cells transduced with the shBcl-2 lentivirus (Fig. 7B).
To quantitate the KSHV virus progeny production, the virus
supernatant of induced BC3-shC or BC3-shBcl2 cells was prepared
at 48 h postinduction, and used as a template for PCR analysis of
the KSHV ORF9. Our data indicated that Bcl-2 knockdown
reduced the productionof virus particles as determined by detection
ofthequantifiedproductoftheK9geneamplifiedbyPCR(Fig.7C).
This was about 2-fold less than the progeny production in the
control cell line. These results indicate that RTA-mediated
enhanced expression of Bcl-2 contributes to virus progeny
production during lytic replication. The two cell lines examined
had a distinctly different pattern of apoptosis when treated with
TPA and butyrate. Under induction, the BJAB cell line which is
negative for KSHV resulted in similar levels of apoptosis which was
about 62–64% when the BJAB-shC cells were compared to the
BJAB-shBcl2 cells (Fig. 7D). Importantly, the results from the
KSHV-infected BC3 cells showed a clear increase in the level of
apoptosis when comparing the BC3-shC cells to the BC3-shBcl2
cells (p,0.05) (Fig.7D). These findings provide convincing evidence
supporting the hypothesis that RTA can upregulate Bcl-2
expression and have a direct role in enhancing cell survival and
thus an increase in virus progeny production.
Figure 3. Northern blot analyses of Bcl-2 RNA. Total RNA was extracted from each cell (HEK 293, RTA-expressing HEK 293, induced and
uninduced BC3, BCBL1, BJAB cells). Blots were first probed against Bcl-2 mRNA, then reprobed with a GAPDH probe. Density of Bcl-2 signal divided by
that of GAPDH control was used to quantify the levels of Bcl-2 mRNA expression. Western blot analysis was used to detect expression of RTA
transcript to show the dose effect.
doi:10.1371/journal.pone.0023892.g003
Figure 4. RTA transactivated the Bcl-2 promoter in a dose-dependent manner. (A, B) Ten million HEK 293 cells or DG75 cells were
transfected with 10 mg of PGL3-Bcl-2, and 0, 5, 10, 15, or 20 mg pcDNA-RTA. Cell lysates were prepared at 24 h posttransfection for the luciferase
assay. Data from three independent groups are exemplified with mean and standard deviation to show the fold activation by comparison of the
promoter activity in the presence of RTA with the value of pGL3B alone. Western blot was used to confirm the transfection efficiency with GAPDH
served as control for equal protein loading.
doi:10.1371/journal.pone.0023892.g004
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Similar to other large DNA herpesviruses, KSHV has two
major life cycles referred to as the latent and lytic replication
cycles. Latency exists in most of the KSHV infected cells which
harbor the viral episomes [59,60], but a minority of cells do
undergo the full lytic program to sustain KS pathological changes
[61,62]. KSHV viral genes are successively activated in the lytic
replication phase which can be triggered by RTA [53]. RTA
regulates the KSHV lytic phase to reactivate the virus from latency
and so initiate replication [55,56,57]. Previous studies showed that
RTA transactivates the transcription of its downstream gene in
two ways, one is through binding RREs, and another is by
interacting with cellular transcription factors, such as K-RBP
[63,64], CEBP-a [33,65], Oct-1 [30], and RBP-Jk [24].
Apoptosis of infected cells can restrict or dampen full blown
virus replication and this can serve as a protective defense
mechanism against virus infection. Consequently, viruses can also
delay programmed cell death by enhancing the expression of
antiapoptotic proteins [66,67,68]. The ability to suppress apoptosis
may be essential to drive the enhanced survival of KSHV-positive
cells so that the virus may replicate and spread, thus resulting in
persistence of the virus in the host. KSHV can employ a number
of molecular strategies which are related to induction of cell
transformation, regulation of cell proliferation, and resistance of
apoptosis. Therefore, there is a high probability that RTA
contributes to virus lytic replication through the activation of
cellular Bcl-2 expression very early during infection.
Human Bcl-2 is expressed on the surface of the mitochondrial
membrane and functions as a major regulator of the delicate
balance between cell survival and apoptosis [47,49]. In this study,
we now present evidence for the interplay between RTA and Bcl-
2. Both Bcl-2 mRNA and protein levels were upregulated in RTA-
expressing human cells and in TPA-induced KSHV-infected cells.
Furthermore, we demonstrated that RTA may in fact directly
activate the Bcl-2 gene promoter. As expected, results of the
reporter assay further established that activation of Bcl-2 by RTA
was dose-dependent, and that the effect was not cell type specific.
Thus, these experiments have now convincingly established an
association between RTA expression and Bcl-2 upregulation.
Figure 5. The CCN9GG-like KSHV RTA responsive element (RRE) and P2 promoter region are indispensable for activation of Bcl-2
transcription by RTA. (A) Illustration of the wild type and mutant Bcl-2 promoters. Nine CCN9GG motifs in Bcl-2 promoter are shown. Numbers
represent the nucleotide positions upstream of the initiating ATG. (B, C) Ten million HEK 293 cells or DG75 cells were transfected with 10 mgo f
indicated mutant Bcl-2 promoter reporter plasmids, and 5, 10, 15, or 20 mg pcDNA-RTA. Cell lysates were prepared at 24 h posttransfection for the
luciferase assay. The deletion of P1 promoter did not result in a major decrease in promoter activity and ever resulted in an increase in promoter
activity in HEK 293 cells. However, deletion of either RREs or P2 promoter resulted in complete loss of Bcl-2 promoter activity in the presence of RTA.
doi:10.1371/journal.pone.0023892.g005
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we identified potential responsive elements within the Bcl-2
promoter. Interestingly, this promoter contains nine CCN9GG-
like motifs and these CCN9GG-like motifs were recently identified
KSHV RRE present in five gene promoters of KSHV [58] . Both
experiments in vitro and in vivo have shown that this RRE was
able to react with RTA so as to regulate the activation of RTA
[58]. This provided the likelihood that a similar strategy may be
used in upregulation of Bcl-2 by RTA. Our data from the reporter
assays with a series of truncated promoters demonstrated that
these CCN9GG-like motifs in fact do have an effect on
transactivation of Bcl-2 by RTA. Deletion of the nine CCN9GG
motifs completely shut down the Bcl-2 promoter activity.
Additionally, deletion of the first and second CCN9GG motifs
also led to a significant decrease in RTA-mediated Bcl-2 promoter
activity. Furthermore, the results of ChIP confirmed the direct
interaction of RTA protein with RREs within the Bcl2 promoter.
This confirms our hypothesis that the CCN9GG motifs are
important and likely to be critical for transactivation of Bcl2 by
RTA. Interestingly, a highly consistent sequence, GNCCN9
GGNG, with an identification as EBV RRE has been reported
[69]. Another previous study on the EBV RTA-responsive
promoters pointed out that the differential responsiveness of the
CCN9GG motifs to RTA transcription and KSHV reactivation
may result from a variation in the N9 sequences [70]. The KSHV
five gene promoters containing the consensus sequence CCN9GG
also contained variations in the N9 sequences [58]. The PAN-RRE
had stronger interactivity with RTA than the K2- and K12-RREs
[23]. A few cellular factors, as mentioned above, can clearly
interact with RTA [53]. Their cis-acting binding domains are
possibly in the vicinity of the CCN9GG sequence [58]. Thus, RTA
can either bind to the CCN9GG motif or these cellular proteins
bound to their cis-acting elements which may result in optimal
activation of the promoter. In addition, our data also showed that
the P2 promoter is indispensable for RTA-mediated transactiva-
tion of Bcl-2. The pGL3-DP1 construct had no detectable
reduction of luciferase activity compared with the full length
Bcl-2 promoter, whereas mutation of P2 promoter region was able
to completely shut down the promoter activity. The P2 promoter
contains both a CCAAT and a TATA box and an octamer motif
[71]. However, the P1 region contains a TATA-less GC-rich
promoter with seven binding sites for the Sp1 transcription factor
[71]. How is it that the P2 promoter has a preference for Bcl-2
transactivation by RTA? We cannot however exclude the
possibility that the TATA box and/or the octamer motif within
the P2 promoter are indispensable for RTA-mediated upregula-
tion of Bcl-2. These studies are yet to be done and will hopefully
provide a deeper understanding of the mechanism.
Depletion of Bcl-2 clearly increases the level of cellular
apoptosis, and decreases virus progeny production in induced
BC3-shBcl2 cells compared with that of the BC3-shC cells. This
provides strong evidence that upregulation of cellular Bcl-2 by
RTA can definitely contribute to KSHV lytic replication. The
utilization of the Bcl-2 pathway by RTA would be a responsible
strategy for prolonging the survival of lytically infected cells and
thus allow enhanced production of virus progeny.
In summary, our study which investigated the interaction
between KSHV RTA and cellular Bcl-2 showed that RTA can
transactivate Bcl-2 transcription through targeting of the RRE
CCN9GG motifs within the Bcl-2 promoter. We also demonstrat-
ed that the P2 promoter region instead of the P1 promoter region
was highly responsive to RTA. The results of ChIP confirmed the
direct interaction of RTA protein with the CCN9GG motifs.
Knockdown of cellular Bcl-2 by lentivirus-delivered small hairpin
RNA (shRNA) resulted in increased cell apoptosis and decreased
virion production in KSHV-infected cells. RTA can upregulate
Bcl-2-mediated block to cellular apoptosis, and so prolong cell
survival leading a further increase in production of virus progeny
(Fig. 8). These findings provide an insight into the molecular
mechanism by which KSHV interferes with the intrinsic apoptosis
signaling pathways to promote viral lytic replication.
Figure 6. The CCN9GG motifs contribute to Bcl-2 promoter
activation by RTA. (A) Scheme showing pGL3-DRRE1,2 and pGL3-DP1
construct used in this study. (B) Fix amounts (10 mg) of indicated
mutant Bcl-2 promoter luciferase constructs were transfected or
cotransfected into ten million HEK 293 cells with 10, 20 mg of pcDNA-
RTA respectively. Cell lysates were prepared and the luciferase assay
was carried out as above mentioned in Fig. 4 legend. Deletion of the
first and second CCN9GG motifs led to a significant decrease in RTA-
mediated Bcl-2 promoter activity. (C) A ChIP assay was carried out using
induced or uninduced BCBL1 cells. RTA-DNA complexes were specif-
ically precipitated with or without RTA antibody. The precipitated DNA
was recovered by PCR with primers covering RRE 1 and 2 (upper panel).
Real-time PCR was performed to quantify the immunoprecipitated
promoter DNA.
doi:10.1371/journal.pone.0023892.g006
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Constructs
Plasmid pcDNA-RTA is an expression vector which encodes
the full-length RTA. The Bcl-2 gene full-length promoter reporter
plasmid, pGL3-Bcl-2 was a kind gift from Ve ´ronique Bourgarel-
Rey (Aix-Marseille Universite ´, Marseille Cedex 05, France). The
truncated reporter plasmids pGL3-DRREs, pGL3-DP1, pGL3-
DP2 and pGL3-DRRE1,2 were obtained by PCR-based site
mutagenesis (Primers see Table 1). Plasmids pGL3-DRREs and
Figure 7. RTA-mediated Bcl-2 upregulation is important for prolonging the survival of lytically infected host cells and to enhance
production of virus progeny. (A) Bcl-2 knockdown cells and control cells with GFP expression were monitored by fluorescence microscopy
showing successful lentivius infection. (B) Western blots (WB) showing expression of Bcl-2 in BJAB-shC, BJAB-shBcl-2, BC3-shC, and BC3-shBcl-2 cells.
GAPDH served as control. (C) Supernatants of RTA and butyrate-induced BC3-shC, and BC3-shBcl2 cells were prepared after induction 48 h for PCR to
analyze the production of KSHV progeny. KSHV genomic DNA isolated from BC3 cells served as control. (D) Different cellular apoptosis pattern in
induced and uninduced BJAB-shBcl2 and BC3-shBcl2 cell lines. The first sub-G1 peak represents apoptotic cell.
doi:10.1371/journal.pone.0023892.g007
RTA-Mediated Upregulation of Bcl-2
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2 promoter (nucleotide 21563,+1 for DRREs; 22744,2680 for
DP2) into the SmaI/HindIII sites of pGL3 basic vector. For
construct pGL3-DP1, first inserting the promoter fragment
(2346,+1) near the start codon into the MluI/HindIII sites of
the pGL3 basic vector (pGL3-P2), then followed by inserting
another PCR fragment (22867,21545) into the KpnI/MluI sites
of pGL3-P2. Construct pGL3-DRRE1,2 was derived by deletion
of the first and second CCN9GG motifs within pGL3-DP1.
Antibodies and cell cultures
RTA antibody was generated from a hybridoma (Lan et al.
Institute Pasteur, Shanghai, China). The Bcl-2 mouse monoclonal
antibody is a product of Santa Cruz Biotechnology, Inc (Santa
Cruz, CA). The GAPDH mouse antibody was obtained from
Novus Biologicals, LLC (Littleton, CO).
Human embryonic kidney fibroblast 293 was obtained from Jon
Aster (Brigham and Women’s Hospital, Boston, MA). BJAB is a
KSHV and EBV negative B cell line and was provided by Elliott
Kieff (Harvard Medical School, Boston, MA). DG75 is a KSHV
negative B cell line. BC3 and BCBL1 are KSHV-positive body
cavity-based lymphoma-derived cell lines obtained from the NIH
AIDS Research and Reference Reagent Program [51]. DG75
were obtained from the American Type Culture Collection. Cells
were cultured as described before [47,52].
Transfection and Induction of KSHV
HEK 293 and DG75 cells were transfected by using a Bio-Rad
Gene Pulser II electroporator. Experimental method for transfec-
tion by electroporation was previously described [53]. BC3,
BCBL1 and BC3-shBcl-2 cells were induced with 20 ng of TPA/
ml and 1.5 mM butyrate [51]. BJAB, BJAB-shC, BC3-shC cells
were used as control. All cells were harvested for experimental use
at 48 h postinduction.
Western blot
After treatment, the cells were harvested and lysed in a RIPA
buffer. The protein concentration of the lysates was measured by
Bradford assay. Samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and then trans-
ferred to polyvinylidene difluoride (PVDF) membranes. Western
boltting was performed using anti-Bcl2, anti-RTA, or anti-
GAPDH antibody and goat anti-mouse IgG secondary antibody
conjugated to IR dye 800 (Rockland Immunochemicals, Inc.,
Gilbertsville, PA). After the membranes were washed, the signals
were scanned with Odyssey infrared image (LI-COR, Inc.,
Lincoln, NE).
Quantitative real-time PCR analysis
Total RNA extraction from cells (HEK 293, RTA-transfected
HEK 293, DG75, RTA-transfected DG75, induced and un-
induced BC3, BCBL1, BJAB cells), generation of cDNA,
preparation of reaction mixture and RT-PCR amplification
condition were described previously with minor modifications
[47,52]. The primer sequences of Bcl-2 and GAPDH genes used
for the real-time PCR are shown in Table 1 [47,52]. Data analyses
were carried out by using a StepOnePlus RT-PCR system
(Applied Biosystems, INC., Foster City, CA) with each sample
tested in triplicates.
Northern blot analysis
A human Bcl-2 gene DNA probe of 539 bp and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) probe of 628 bp were
generated by PCR using HEK 293 cells cDNA as template.
Primer 3 software was used to design the primers (listed in Table 1).
Both DNA probes were confirmed by sequencing (sequencing
core, Upenn). The DNA probes were radiolabeled by random
priming method with NEB #1500 L kit (New England Biolabs,
Ipswich, MA). Ten microgram of total RNA from each cell (HEK
293, RTA-transfected HEK 293, induced or uninduced BC3,
BCBL1, BJAB cells) was resolved by formaldehyde-agarose gel
electrophoresis and transferred to a 0.22 mm pore nitrocellulose
membrane. After prehybridization, the membrane was hybridized
successively with
32P-radiolabeled DNA probes, followed by
washes twice with SSC 26 buffer (0.3 M NaCl, 30 mM sodium
citrate, pH 7.0, 0.1% SDS) for 5 min at room temperature, then
with SSC 0.56 buffer, 0.1% SDS for 10 min at 60uC. The
autoradiographic images were analyzed by using a PhosphorIma-
ger with supplementary ImageQuant software (Molecular Dy-
namics Inc., Sunnyvale, CA).
Luciferase assay
Ten million HEK 293 and DG75 cells were cotransfected with
10 mg of the reporter plasmids and increasing amounts of RTA
plasmids respectively. Cell lysates were prepared at 24 h
posttransfection. Twenty five microliters of luciferase assay
Figure 8. Hypothetical model showing RTA mediated upregulation of cellular Bcl-2. P2 promoter and the CCN9GG-like RREs are
indispensable for upregulation of Bcl-2 by RTA. Enhanced expression of Bcl-2 prolongs cell survival and virus progeny production. RRE, RTA
responsive element.
doi:10.1371/journal.pone.0023892.g008
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luminometer (Molecular Devices, Inc., Sunnyvale, CA) was used
to measure luminescence level. The results showed the mean and
standard deviation (SD) of the data of three independent
experiments. Western blot analysis was used to confirm the
expression of the proteins.
Chromatin immunoprecipitation (ChIP)
At 48 h post-induction, BCBL1 cells were fixed by adding 37%
formaldehyde to a final concentration of 1% for 10 min. The cross-
linking reaction was stopped by adding glycine to a final
concentration of 0.125 M for 5 min. Cells were washed three times
with 16 ice-cold PBS and resuspended in cell lysis buffer [5 Mm
PIPES (pH 8.0), 85 mM KCl, 0.5% NP-40] containing 1 mM
PMSF and 1 mg/ml protease inhibitors for 10 min at 4uC. After
centrifugation, the cell pellets were resuspended in nuclear lysis
buffer [50 mM Tris/HCl (pH 8.1), 10 mM EDTA, 1% SDS] and
incubated for 10 min at 4uC. The resulting solution was diluted 5-
fold with dilution buffer [16.7 mM Tris/HCl (pH 8.1), 167 mM
NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100, 1 mM
PMSF, 1 mg/ml protease inhibitors] and sonicated. After centrifu-
gation, the supernatant was pre-cleared with mouse IgG and
immobilized Protein A. Immunoprecipitation was performed by
incubation at 4uC with anti-RTA antibody or mouse IgG antibody.
Immune complexes were collected by a further incubation with
immobilized Protein A for 1–2 h at 4uC. The beads were washed
four times with IP buffer [25 mM Tris/HCl (pH 7.2), 150 mM
NaCl] and resuspended in elution buffer (1% SDS/0.1 M
NaHCO3). After centrifugation, the supernatant was neutralized
with 1 M Tris/HCl (pH 7.2). RNase A and NaCl were added,
followed by incubation at 65uC overnight to reverse the cross-linked
DNA–protein complex. Proteinase K was added, followed by
incubation at 55uC for 1–2 h. DNA extraction was carried out using
phenol: chloroform and analysed by PCR using specific primers
covering RRE1 and RRE 2 in the full length reporter vector. The
DNA was quantified by SYBR green real-time PCR. For calculation
oftherelative DNAamountfromquantitativereal-time PCR,theCt
(threshold cycle) value of antibody-precipitated sample was normal-
ized by the Ct value of the input, and the normalized Ct value of
induced and uninduced groups were compared.
RNA interference lentiviral constructs and transduction
Bcl-2 small hairpin RNA (shBcl-2) and control shRNA (shC)
were synthesized by Sigma (St. Louis, MO) as previously described
[54]. A shRNA lentiviral vector expressing Bcl-2 small hairpin,
pGIPZ, was a product of Open Biosystems, Inc (Huntsville, AL).
Protocols for lentiviruses infection were previously described
[47,52]. In our experiments, BC3-shBcl2, BJAB-shBcl2 and their
corresponding control cell lines, BC3-shC and BJAB-shC were
generated for further analysis.
PCR amplification of viral progeny DNA
To investigate whether Bcl-2 upregulation can increase the
production of viral progeny, the KSHV encoded ORF9 was
Table 1. Primers for PCR amplification and analysis.
Primer Squence* Note
Bcl-2-F1 59-GGTGAACTGGGGGAGGATTGT-39 Real-time PCR
Bcl-2-R1 59-CTTCAGAGACAGCCAGGAGAA-39
GAPDH-F1 59-TGCACCACCAACTGCTTAG-39 Real-time PCR
GAPDH-R1 59-GATGCAGGGATGATGTTC-39
Bcl-2-F2 59-TCTGCGAAGAACCTTGTGTG-39 Northern probe
Bcl-2-R2 59-CTCCACCAGTGTTCCCATCT-39
GAPDH-F2 59- TGGAAGGACTCATGACCACA-39 Northern probe
GAPDH-R2 59- AGGGGTCTACATGGCAACTG-39
Bcl-2D15 9-CCCAAGCTTCCTTCCCAGAGGAAAAGC-39 DRREs clone
Bcl-2D25 9- TGAATGAACCGTGTGACGTT -39
Bcl-2D35 9-TGCTAGGGGCTATTCATGCT-39 DP2 clone
Bcl-2D45 9-CCCAAGCTTCCAGATCGATTCCCAGAC-39
Bcl-2D55 9-CCCGGTACCTCGAGCCCTATTAAGTAAG-39 DP1 clone
Bcl-2D65 9-CCCACGCGTAACGTCACACGGTTCATTCA-39
Bcl-2D75 9-CCCACGCGTGTGTACAGGGAAACGCACCT-39
Bcl-2D8( D1) 59-CCCAAGCTTCCTTCCCAGAGGAAAAGC-39
Bcl-2D95 9-CCCGGTACCGCCCTATTAAGTAAGCCGCTGT-39 DRRE1,2 clone
Bcl-2D10 59-CCCACGCGTGGTGGGCTCCTAAAGGTCTC-39
Bcl-2D11 59-CCCACGCGTAGGGACAGAGGGAAAACATTG-39
Bcl-2D12 (D1) 59-CCCAAGCTTCCTTCCCAGAGGAAAAGC-39
K9-F 59-CCAGGAAAAGAGCAGTCAGG-39 PCR for virus progeny
K9-R 59-CGCGTTGAGCACTTGAATTA-39
ChIP-F 59-GCCAACTAGGATTGGCTACG-39 ChIP assay
ChIP-R 59-CGTGTCCACCTGAACACCTA-39
*Restriction sites are underlined.
doi:10.1371/journal.pone.0023892.t001
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BC3-shC and BC3-shBcl2 cells. Cells were induced and further
incubated for 2 days at 37uC under 5% CO2. The supernatant was
then collected and passed through a 0.45-mm-pore-size filter, and
viral particles were spun down at 23,500 rpm for 20 min. Intact
cells were discarded to prevent possible lysis and contamination
from cellular viral DNA. The pellet was resuspended in 50 mlo f
0.26PBS, heated to 95uC for 15 min, and switched to 56uC for
1 h with proteinase K treatment (10 mg/ml). The enzyme was
then destroyed by treatment at 95uC for 30 min. A 10-ml portion
of virus lysate was used for PCR amplification of the KSHV-
specific region of ORF9. The primers for amplification of ORF9
are listed in Table 1. KSHV genomic DNA isolated from BC3
cells served as control. The net density of the PCR product bands
was quantitated using Kodak 1D 3.6 software (Eastman Kodak
Company, Rochester, NY).
Apoptosis assay
Cellular apoptosis patterns were examined in induced and
uninduced BC3-shBcl2, BJAB-shBcl2 and their control cell lines,
BC3-shC and BJAB-shC using propidium iodide (PI) staining and
flow ctyometry analysis using previously published protocols from
our lab [47,52]. Briefly, 10
6 cells were collected, washed, fixed,
then treated with PI staining and RNase A digestion, followed by
examination of cellular apoptotic levels. Each sample was analyzed
six times. Statistical analysis was carried out using one-way
ANOVA (Analysis of Variance).
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